Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPROSTADIL vs DICLOFENAC SODIUM AND MISOPROSTOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular c AMP, and relaxing smooth muscle. It also inhibits platelet aggregation.
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Misoprostol is a synthetic prostaglandin E1 analog that replaces protective prostaglandins in the gastric mucosa, reducing gastric acid secretion and increasing mucus and bicarbonate production.
Treatment of erectile dysfunction (intracavernosal injection or urethral suppository),Palliative therapy to maintain patency of ductus arteriosus in neonates with congenital heart defects pending surgery (intravenous infusion)
FDA: Osteoarthritis,FDA: Rheumatoid arthritis,Off-label: Acute pain, Ankylosing spondylitis
Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.
Diclofenac sodium 50 mg/misoprostol 200 mcg orally twice daily with food for osteoarthritis and rheumatoid arthritis; diclofenac sodium 75 mg/misoprostol 200 mcg orally twice daily for rheumatoid arthritis.
5-10 minutes; rapidly metabolized in the lungs, clinical effect lasts longer due to continuous infusion.
Diclofenac: Terminal t1/2 ~1-2 h (short, requiring frequent dosing). Misoprostol: Terminal t1/2 ~20-40 min (rapidly de-esterified to active misoprostol acid, with acid t1/2 ~20-30 min).
Primarily metabolized via oxidation in the lungs, liver, and kidneys. Approximately 80% inactivated by 15-hydroxy dehydrogenase enzyme on first pass through the lungs.
Diclofenac is primarily metabolized by cytochrome P450 CYP2C9, with minor contributions from CYP3A4. Misoprostol is rapidly de-esterified to its active metabolite, misoprostol acid, which undergoes further beta-oxidation and reduction.
Primarily via urine (90%) as metabolites; 10% unchanged; minimal fecal excretion.
Diclofenac: ~65% renal (primarily as glucuronide conjugates, with <1% unchanged), ~35% biliary/fecal. Misoprostol: >80% renal as inactive metabolites.
80-90% bound to albumin.
Diclofenac: >99% bound to albumin. Misoprostol acid: ~80-90% bound to albumin.
0.3-0.4 L/kg (large, extensive tissue distribution).
Diclofenac: Vd ~1.3 L/kg (extensive tissue distribution). Misoprostol: Vd not well defined for acid; parent drug rapidly hydrolyzed.
IV: 100%; intracavernosal: nearly complete; intra-arterial: high first-pass lung metabolism limits systemic bioavailability.
Diclofenac: Oral ~50-60% (first-pass metabolism). Misoprostol: Oral ~70-80% (rapidly absorbed and de-esterified to active acid).
No specific GFR-based dose modifications established; use with caution in renal impairment due to potential for hypotension.
GFR < 30 m L/min: contraindicated. GFR 30-59 m L/min: use with caution, no specific dose adjustment; monitor renal function. GFR >= 60 m L/min: no adjustment.
No specific Child-Pugh based dose modifications established; use with caution in hepatic impairment due to altered metabolism.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: use with caution, reduce dose or increase interval; not recommended. Child-Pugh Class C: contraindicated.
For patent ductus arteriosus: initial IV infusion 0.05-0.1 mcg/kg/min; titrate to response; for erectile dysfunction: not typically used in pediatric patients.
Not approved for pediatric patients; safety and efficacy not established. No standard weight-based dosing.
Start at lower end of dosing range (e.g., initial IV bolus 20 mcg) due to increased sensitivity and comorbidity; monitor blood pressure closely.
Initiate at lowest effective dose; consider renal function (age-related decline); avoid if GFR < 30 m L/min; increased risk of GI bleeding, renal impairment, and hypotension.
None.
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Diclofenac is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk.
Risk of priapism (prolonged erection >4 hours) requiring immediate medical attention,Risk of penile fibrosis or angulation with long-term use,Use with caution in patients with bleeding disorders or on anticoagulants due to bleeding risk,Do not use in neonates with respiratory distress syndrome or persistent fetal circulation,Monitor blood pressure during intravenous use due to hypotension risk
Cardiovascular risk; gastrointestinal risk; hypertension; fluid retention; renal toxicity; hepatic toxicity; anaphylactoid reactions; skin reactions; hematologic toxicity; use in pregnancy (misoprostol can cause uterine contractions, abortion, or fetal harm); avoidance with aspirin or other NSAIDs; elderly patients; pre-existing asthma.
Hypersensitivity to alprostadil,Conditions predisposing to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia),Penile implant or anatomical penis deformity (for erectile dysfunction formulations),Neonates with persistent fetal circulation or respiratory distress syndrome (for intravenous formulation),In women who are pregnant or breastfeeding (not indicated)
Hypersensitivity to diclofenac, misoprostol, other NSAIDs, or prostaglandins; history of asthma, urticaria, or allergic-type reactions with NSAIDs; perioperative pain in CABG surgery; active GI bleeding; severe heart failure; advanced renal disease; pregnancy (misoprostol can cause abortion).
No known food interactions. Grapefruit may increase levels via CYP3A4 inhibition, but clinical significance is low for topical/intracavernosal use.
Avoid alcohol and high-fat meals as they may increase GI irritation. Take with food or milk to reduce dyspepsia. No specific food restrictions other than avoiding known GI irritants.
Alprostadil is not indicated for use in pregnancy; systemic exposure poses risk of uterine hyperstimulation and fetal distress. No adequate human studies; animal studies show embryotoxicity. Avoid in pregnancy unless no safer alternative.
Diclofenac: Risk category C in first and second trimesters; category D in third trimester. Avoid in third trimester due to premature closure of ductus arteriosus and oligohydramnios. Misoprostol: Contraindicated in pregnancy as it stimulates uterine contractions and can cause miscarriage, premature labor, and birth defects (e.g., Möbius syndrome). High risk of fetal harm throughout pregnancy.
No data on excretion in human milk; M/P ratio unknown. Due to short half-life and local administration, systemic absorption minimal. Use with caution in breastfeeding.
Diclofenac: Limited excretion into breast milk; M/P ratio approximately 0.1-0.2. Considered compatible with breastfeeding with caution. Misoprostol: Excreted into breast milk; M/P ratio not well defined. Avoid use during breastfeeding due to potential for gastrointestinal effects in infant.
No established dosing in pregnancy; contraindicated in pregnant women. No dose adjustment data available for pregnant populations.
No dose adjustments are recommended for pharmacokinetic changes in pregnancy. However, diclofenac should be avoided in third trimester and misoprostol is contraindicated throughout pregnancy. Use lowest effective dose of diclofenac if necessary.
Alprostadil causes vasodilation via c AMP increase; watch for hypotension and priapism. For erectile dysfunction, inject into corpus cavernosum, not dorsal vein. For patent ductus arteriosus, monitor respiratory drive as apnea is common in neonates.
Diclofenac sodium/misoprostol is contraindicated in pregnancy (misoprostol is abortifacient). Use lowest effective dose; misoprostol component mitigates NSAID-induced GI injury but not cardiovascular risk. Avoid in patients with active GI bleed or inflammatory bowel disease. Renal function monitoring is essential, especially in elderly or volume-depleted patients. Misoprostol may cause diarrhea and uterine cramping.
Seek immediate medical help if erection lasts more than 4 hours.,Do not use if you have a penile implant or conditions like sickle cell disease.,Avoid driving until you know how this medication affects you.,For injection, rotate injection sites and use within 24hrs of opening vial.,Report any signs of infection at injection site.
Do not take if pregnant or planning pregnancy; misoprostol can cause miscarriage.,Take with food to reduce stomach upset; avoid alcohol.,Report severe abdominal pain, black/tarry stools, or vomiting blood immediately.,Do not take other NSAIDs or aspirin unless prescribed.,Notify healthcare provider if diarrhea persists or becomes severe.
"Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, may reduce the vasodilatory efficacy of alprostadil, a prostaglandin E1 analog. This interaction likely results from pirfenidone-induced downregulation of prostaglandin receptors or modulation of cyclic AMP signaling pathways, leading to diminished smooth muscle relaxation and reduced therapeutic response to alprostadil. Consequently, patients may experience suboptimal vasodilation, potentially compromising treatment for conditions like erectile dysfunction or peripheral arterial disease."
"Concomitant administration of Alprostadil, a vasodilator, and Aminosalicylic acid, a salicylate, may produce additive antiplatelet effects, increasing the risk of bleeding. Alprostadil inhibits platelet aggregation via cAMP elevation, while Aminosalicylic acid inhibits cyclooxygenase, reducing thromboxane A2 synthesis. Clinically, this may result in prolonged bleeding time, easy bruising, or hemorrhage, especially in patients with underlying coagulopathies or those on other anticoagulants."
"Loxoprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins. Alprostadil, a synthetic prostaglandin E1 analog, exerts its therapeutic effects through vasodilation and inhibition of platelet aggregation. The concurrent use of loxoprofen may attenuate the pharmacological activity of alprostadil by diminishing prostaglandin-mediated responses, potentially leading to reduced efficacy in conditions such as erectile dysfunction or peripheral vascular disease."
"Ximelagatran, an oral direct thrombin inhibitor, increases the risk of bleeding when coadministered with diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). The combination potentiates anticoagulant activity through additive inhibition of platelet aggregation and thrombin-mediated coagulation, elevating the risk of gastrointestinal hemorrhage and other serious bleeding events. Patients, particularly those with renal impairment or advanced age, require close monitoring for signs of bleeding."
"Acebutolol, a cardioselective beta-blocker, may attenuate the antihypertensive effect of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). Diclofenac inhibits cyclooxygenase, reducing prostaglandin synthesis, which can lead to sodium retention and increased vascular resistance, thereby counteracting the blood pressure-lowering effects of acebutolol. This interaction may result in diminished blood pressure control, potentially requiring dose adjustments of antihypertensive therapy."
"Enzalutamide, a potent CYP3A4 inducer, significantly reduces the exposure of diclofenac, a CYP2C9 substrate, by increasing its hepatic metabolism. This interaction can lead to subtherapeutic diclofenac concentrations, thereby diminishing its analgesic and anti-inflammatory efficacy. Clinically, patients may experience inadequate pain control or exacerbation of inflammatory conditions, such as arthritis, when these agents are coadministered."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPROSTADIL vs DICLOFENAC SODIUM AND MISOPROSTOL, answered by our medical review team.
ALPROSTADIL is a Prostaglandin Analog that works by Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular c AMP, and relaxing smooth muscle. It also inhibits platelet aggregation.. DICLOFENAC SODIUM AND MISOPROSTOL is a Prostaglandin Analog that works by Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Misoprostol is a synthetic prostaglandin E1 analog that replaces protective prostaglandins in the gastric mucosa, reducing gastric acid secretion and increasing mucus and bicarbonate production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPROSTADIL and DICLOFENAC SODIUM AND MISOPROSTOL depend on the specific clinical indication. These are both Prostaglandin Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPROSTADIL is: Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.. The standard adult dose of DICLOFENAC SODIUM AND MISOPROSTOL is: Diclofenac sodium 50 mg/misoprostol 200 mcg orally twice daily with food for osteoarthritis and rheumatoid arthritis; diclofenac sodium 75 mg/misoprostol 200 mcg orally twice daily for rheumatoid arthritis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining ALPROSTADIL and DICLOFENAC SODIUM AND MISOPROSTOL. The therapeutic efficacy of Alprostadil can be decreased when used in combination with Diclofenac. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. ALPROSTADIL is classified as Category C. Alprostadil is not indicated for use in pregnancy; systemic exposure poses risk of uterine hyperstimulation and fetal distress. No adequate human studies; animal studies show embry. DICLOFENAC SODIUM AND MISOPROSTOL is classified as Category D/X. Diclofenac: Risk category C in first and second trimesters; category D in third trimester. Avoid in third trimester due to premature closure of ductus arteriosus and oligohydramnio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.